Biology subjects

Manczinger, M.

Publications and source records attributed to Manczinger, M..

5 recordsLinked to original sources

bioRxiv2025

A Morpho-Proteomic Atlas of Mitosis at Sub-Minute Resolution

Precise spatiotemporal protein organization is critical for fundamental biological processes including cell division1,2. Indeed, aberrant mitosis and mitotic factors are involved in diverse diseases, including various cancers3,4, Alzheimers disease5, and rare diseases6. During mitosis, complex spatial rearrangements and regulation ensure the accurate separation of replicated sister chromatids to produce genetically identical daughter cells7-9. Previous studies employed high-throughput methodologies to follow specific proteins during mitosis10-15. Still a temporally refined systems-level approach capable of monitoring morphological and proteomic changes throughout mitosis has been lacking. Here, we achieved unprecedented resolution by phenotypically decomposing mitosis into 40 subsections of a regression plane for proteomic analysis using deep learning and regression techniques. Our deep visual proteomics (DVP) workflow16, revealed rapid, dynamic proteomic changes throughout mitosis. We quantified 4,350 proteins with high confidence, demonstrating that 147 show significant dynamic abundance changes during mitotic progression. Clustering revealed coordinated patterns of protein regulation, while network analysis uncovered tight regulation of core cell cycle proteins and a link between cell cycle and cancer-linked mutations. Immunofluorescence validated abundance changes and linked previously uncharacterised proteins, like C19orf53, to mitosis. To facilitate data navigation, we developed Mito-Omix, a user-friendly online platform that integrates intricate morphological and molecular data. Our morphological and proteomic dataset spans mitosis at high resolution, providing a rich resource for understanding healthy and aberrant cell division.

cell biology↗

bioRxiv2023

Antibiotics of the future are prone to resistance in Gram-negative pathogens

Despite the ongoing development of new antibiotics, the future evolution of bacterial resistance may render them ineffective. We demonstrate that antibiotic candidates currently under development are as prone to resistance evolution in Gram-negative pathogens as clinically employed antibiotics. Resistance generally stems from both genomic mutations and the transfer of antibiotic resistance genes from microbiomes associated with humans, both factors carrying equal significance. The molecular mechanisms of resistance overlap with those found in commonly used antibiotics. Therefore, these mechanisms are already present in natural populations of pathogens, indicating that resistance can rapidly emerge through selection of pre-existing bacterial variants. However, certain combinations of antibiotics and bacterial strains are less prone to developing resistance, emphasizing the potential of narrow-spectrum antibacterial therapies that could remain effective. Our comprehensive framework allows for predicting future health risks associated with bacterial resistance to new antibiotics.

microbiology↗

bioRxiv2022

Synergy of HLA class I and II shapes the timing of antitumor immune response

The presentation of mutated cancer peptides to T cells by human leukocyte antigen (HLA) class I and II molecules is necessary for antitumor immune response. Both classes are diverse and the variants have distinct peptide-binding specificities. HLA class I diversity was suggested to influence antitumor immunity, however, the findings are controversial. We examined the joint effect of the two HLA classes in melanoma patients. Numerous combinations were associated with better or worse survival in metastatic melanoma patients receiving immune checkpoint blockade (ICB) immunotherapy and they also predicted the survival of ICB-naive patients. Carrying detrimental and beneficial combinations had markedly different effects in primary and metastatic samples. Detrimental combinations were associated with cytotoxic immune response in primary tumors, while metastases showed signs of immune evasion and ineffective antitumor immunity. On the contrary, beneficial combinations were associated with an active cytotoxic immune response only in metastatic samples. HLA class I and II variants in both detrimental and beneficial combinations presented melanoma-associated mutations effectively. However, detrimental combinations were more likely to present immunogenic ones. Our results provide evidence of the joint effect of HLA class I and II variants on antitumor immunity. They potentially influence the strength and timing of antitumor immune response with implications on response to therapy and patient survival.

cancer biology↗

bioRxiv2020

Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumour immunity

The human leukocyte antigen class I (HLA-I) genes shape our immune response against pathogens and cancer. Certain HLA-I variants can bind a much wider range of peptides than others, a feature that could be favorable against a range of viral diseases. However, the implications of this phenomenon on cancer immune response is unknown. In this paper, we quantified peptide repertoire breadth (or promiscuity) of a representative set of HLA-I alleles, and found that cancer patients that carry HLA-I alleles with high peptide binding promiscuity are characterized by significantly worse prognosis after immune checkpoint inhibitor treatment. This trend can be explained by a reduced capacity of promiscuous HLA-I molecules to discriminate between human self and tumour peptides, yielding a shift in regulation of T-cells in the tumour microenvironment from activation to tolerance. In summary, HLA-I peptide binding specificity shapes neopeptide immunogenicity and the self-immunopeptidome repertoire in an antagonistic manner. It could also underlie a negative trade-off between antitumour immunity and the genetic susceptibility to viral infections.Competing Interest StatementThe authors have declared no competing interest.View Full Text

cancer biology↗

bioRxiv2018

Pathogen diversity drives the evolution of promiscuous peptide binding of human MHC-II alleles

Major histocompatibility complex (MHC) molecules mediate the adaptive immune response against pathogens. Certain MHC alleles are generalists: they present an exceptionally large variety of antigenic peptides. However, the functional implications of such elevated epitope binding promiscuity in the MHC molecules are largely unknown. According to what we term the pathogen-driven promiscuity hypothesis, exposure to a broad range of pathogens favors the evolution of highly promiscuous MHC variants. Consistent with this hypothesis, we found that in pathogen-rich geographical regions, humans are more likely to carry promiscuous MHC class II DRB1 alleles, and the switch between high and low promiscuity levels has occurred repeatedly and in a rapid manner during human evolution. We also show that selection for promiscuous peptide binding shapes MHC genetic diversity. In sum, our study offers a conceptually novel mechanism to explain the global distribution of allelic variants of a key human immune gene by demonstrating that pathogen pressure maintains promiscuous MHC class II alleles. More generally, our work highlights the hitherto neglected role of epitope binding promiscuity in immune defense, with implications for medical genetics and epidemiology.

evolutionary biology↗